Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rare Lymphoma Risk Haunts Remicade Expansion To Pediatric Ulcerative Colitis

Executive Summary

Determining how to handle the risk of rare, but deadly, hepatosplenic T-cell lymphoma with Centocor’s Remicade (infliximab) will be one of the tasks FDA faces as it decides whether to expand the biologics’ indication for ulcerative colitis to pediatric patients.
Advertisement

Related Content

Humira Will Get Advisory Committee Review For Ulcerative Colitis
FDA Boosts Surveillance Requirements For TNF Blockers In Effort To Track Lymphoma
FDA Advisory Committee Waivers Reflect Recruitment Challenges
FDA Advisory Committee Waivers Reflect Recruitment Challenges
FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis

Topics

Advertisement
UsernamePublicRestriction

Register

PS053629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel